Accelerate Diagnostics, Inc

Accelerate Diagnostics, Inc. (the “Company”) is filing this Notification of Late Filing on Form 12b-25 (this “Form 12b-25”) with respect to its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 (the “Form 10-Q”). The Company has determined that it will be unable to file its Form 10-Q within the prescribed time period without unreasonable effort or expense for the reasons set forth below. As reported in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 8, 2025, on such date, the Company and certain of its subsidiaries (collectively, the “Company Parties”) filed voluntary petitions (the “Bankruptcy Petitions”) under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the “Court” and such cases, the “Cases”). Additionally, as reported in such Current Report on Form 8-K, on May 8, 2025 prior to the filing of the Bankruptcy Petitions, the Company entered into that certain term sheet with an affiliate of Indaba Capital Management, L.P., the Company’s existing secured noteholder (the “Buyer”), to sell substantially all of the assets of the Company. As reported in the Company’s Current Report on Form 8-K filed with the SEC on June 4, 2025, on May 30, 2025, the Company Parties entered into a “stalking horse” asset purchase agreement (the “Asset Purchase Agreement”) with Buyer to sell substantially all of the assets of the Company (the “Sale Transaction”). As reported in the Company’s Current Report on Form 8-K filed with the SEC on August 18, 2025, on July 14, 2025, the Court entered an order approving the Sale Transaction, and on August 8, 2025, the Company Parties entered into an Amended and Restated Asset Purchase Agreement (the “A&R Asset Purchase Agreement”)

Accelerate Diagnostics, Inc. (the “Company”) is filing this Notification of Late Filing on Form 12b-25 (this “Form 12b-25”) with respect to its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 (the “Form 10-Q”). The Company has determined that it will be unable to file its Form 10-Q within the prescribed time period without unreasonable effort or expense for the reasons set forth below. As reported in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 8, 2025 (the “Form 8-K”), on such date, the Company and certain of its subsidiaries filed voluntary petitions (the “Bankruptcy Petitions”) under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware (such court, the “Court” and such cases, the “Cases”). Additionally, as reported in the 8-K, on May 8, 2025 prior to the filing of the Bankruptcy Petitions, the Company entered into that certain term sheet (the “Stalking Horse Term Sheet”) with an affiliate of Indaba Capital Management, L.P. (“Indaba”), the Company’s existing secured noteholder. Subject to the Stalking Horse Term Sheet, which remains subject to the approval of the Court, Indaba has agreed to acquire substantially all assets of the Company. The aggregate consideration for the Purchased Assets (as defined in the Stalking Horse Term Sheet) shall consist of: (a) a credit bid equaling $36.9 million in the aggregate; and (b) assumption of the Assumed Liabilities (as defined in the Stalking Horse Term Sheet). The transaction is being implemented in the Chapter 11 Cases under Section 363 of the Bankruptcy Code and will be subject to approval by the Court and compliance with agreed upon and Court-approved bidding procedures allowing for the submission of higher or otherwise better offers, and other agreed-upon conditions